| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Status Epilepticus | 35 | 2023 | 145 | 6.640 |
Why?
|
| Electroencephalography | 59 | 2023 | 898 | 5.540 |
Why?
|
| Anticonvulsants | 40 | 2023 | 431 | 4.480 |
Why?
|
| Drug Resistant Epilepsy | 13 | 2023 | 181 | 3.540 |
Why?
|
| Seizures | 31 | 2023 | 989 | 2.970 |
Why?
|
| Epilepsy | 29 | 2023 | 883 | 2.810 |
Why?
|
| Neurology | 8 | 2022 | 113 | 2.790 |
Why?
|
| Critical Care | 12 | 2022 | 770 | 2.100 |
Why?
|
| Spasms, Infantile | 6 | 2023 | 165 | 2.040 |
Why?
|
| Laser Therapy | 3 | 2023 | 411 | 1.340 |
Why?
|
| Monitoring, Physiologic | 14 | 2022 | 502 | 1.250 |
Why?
|
| Child | 100 | 2023 | 29154 | 1.190 |
Why?
|
| Tuberous Sclerosis | 3 | 2023 | 136 | 1.170 |
Why?
|
| Brain Diseases | 9 | 2023 | 403 | 1.120 |
Why?
|
| Stereotaxic Techniques | 4 | 2020 | 172 | 0.950 |
Why?
|
| Brain Waves | 4 | 2018 | 50 | 0.940 |
Why?
|
| Transcranial Magnetic Stimulation | 3 | 2009 | 75 | 0.930 |
Why?
|
| Child, Preschool | 65 | 2023 | 16273 | 0.930 |
Why?
|
| Hemispherectomy | 1 | 2023 | 25 | 0.900 |
Why?
|
| Phenytoin | 4 | 2020 | 71 | 0.900 |
Why?
|
| Clinical Protocols | 4 | 2021 | 467 | 0.850 |
Why?
|
| Landau-Kleffner Syndrome | 4 | 2014 | 8 | 0.850 |
Why?
|
| Pediatrics | 5 | 2014 | 1141 | 0.800 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2013 | 209 | 0.780 |
Why?
|
| Epilepsy, Generalized | 6 | 2023 | 71 | 0.770 |
Why?
|
| Critical Illness | 4 | 2015 | 714 | 0.770 |
Why?
|
| Electric Stimulation Therapy | 3 | 2016 | 116 | 0.760 |
Why?
|
| Benzodiazepines | 7 | 2023 | 170 | 0.740 |
Why?
|
| Brain | 13 | 2021 | 4113 | 0.730 |
Why?
|
| Infant | 44 | 2023 | 13310 | 0.720 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 1085 | 0.670 |
Why?
|
| Hypnotics and Sedatives | 3 | 2015 | 218 | 0.670 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 37 | 0.660 |
Why?
|
| Neurophysiological Monitoring | 1 | 2018 | 23 | 0.650 |
Why?
|
| Coma | 1 | 2018 | 61 | 0.640 |
Why?
|
| Intensive Care Units, Pediatric | 4 | 2018 | 441 | 0.640 |
Why?
|
| Brain Ischemia | 2 | 2018 | 292 | 0.620 |
Why?
|
| Encephalitis | 4 | 2023 | 143 | 0.610 |
Why?
|
| Propofol | 4 | 2013 | 80 | 0.580 |
Why?
|
| Humans | 138 | 2023 | 261506 | 0.580 |
Why?
|
| Seizures, Febrile | 3 | 2021 | 20 | 0.580 |
Why?
|
| Cerebral Cortex | 12 | 2012 | 621 | 0.530 |
Why?
|
| Epilepsies, Partial | 7 | 2018 | 111 | 0.530 |
Why?
|
| Maple Syrup Urine Disease | 2 | 2012 | 15 | 0.520 |
Why?
|
| Adolescent | 54 | 2023 | 31252 | 0.520 |
Why?
|
| Brain Injuries | 1 | 2021 | 787 | 0.500 |
Why?
|
| Hippocampus | 1 | 2020 | 915 | 0.500 |
Why?
|
| Agnosia | 1 | 2014 | 11 | 0.490 |
Why?
|
| Time-to-Treatment | 4 | 2021 | 292 | 0.490 |
Why?
|
| Intensive Care Units | 2 | 2016 | 717 | 0.480 |
Why?
|
| Hypothalamic Diseases | 3 | 2022 | 66 | 0.480 |
Why?
|
| Hamartoma | 3 | 2022 | 115 | 0.470 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 289 | 0.470 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 3 | 2023 | 103 | 0.450 |
Why?
|
| Sleep | 5 | 2014 | 413 | 0.440 |
Why?
|
| Spasm | 2 | 2023 | 59 | 0.440 |
Why?
|
| Retrospective Studies | 32 | 2023 | 37905 | 0.430 |
Why?
|
| Magnetic Resonance Imaging | 23 | 2023 | 7702 | 0.430 |
Why?
|
| Expert Testimony | 1 | 2013 | 90 | 0.420 |
Why?
|
| Biological Clocks | 1 | 2012 | 45 | 0.410 |
Why?
|
| Diazepam | 4 | 2023 | 39 | 0.400 |
Why?
|
| Male | 70 | 2023 | 123000 | 0.390 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2013 | 273 | 0.390 |
Why?
|
| Midazolam | 4 | 2021 | 75 | 0.380 |
Why?
|
| Epileptic Syndromes | 2 | 2021 | 26 | 0.380 |
Why?
|
| Infant, Newborn | 17 | 2022 | 8223 | 0.380 |
Why?
|
| Treatment Outcome | 23 | 2023 | 32848 | 0.370 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2022 | 186 | 0.370 |
Why?
|
| Epilepsy, Frontal Lobe | 3 | 2007 | 11 | 0.360 |
Why?
|
| Carbamazepine | 2 | 2007 | 49 | 0.360 |
Why?
|
| Nervous System Malformations | 2 | 2009 | 133 | 0.340 |
Why?
|
| Pentobarbital | 3 | 2013 | 29 | 0.340 |
Why?
|
| Valproic Acid | 3 | 2013 | 263 | 0.340 |
Why?
|
| Societies, Medical | 3 | 2018 | 1335 | 0.330 |
Why?
|
| Nocturnal Paroxysmal Dystonia | 1 | 2007 | 1 | 0.320 |
Why?
|
| Female | 68 | 2023 | 141928 | 0.300 |
Why?
|
| Nervous System Diseases | 3 | 2022 | 500 | 0.300 |
Why?
|
| Functional Laterality | 4 | 2020 | 316 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 2403 | 0.300 |
Why?
|
| Specialization | 1 | 2008 | 130 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2020 | 4938 | 0.280 |
Why?
|
| Emergency Treatment | 2 | 2018 | 105 | 0.280 |
Why?
|
| Fructose | 3 | 2002 | 72 | 0.280 |
Why?
|
| Medicine | 1 | 2008 | 137 | 0.280 |
Why?
|
| Vigabatrin | 2 | 2023 | 15 | 0.270 |
Why?
|
| Acute Disease | 6 | 2018 | 2422 | 0.270 |
Why?
|
| Vagus Nerve | 2 | 2003 | 63 | 0.260 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2006 | 203 | 0.260 |
Why?
|
| Education, Medical, Graduate | 1 | 2011 | 671 | 0.260 |
Why?
|
| Thalamus | 3 | 2012 | 132 | 0.250 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 1999 | 269 | 0.250 |
Why?
|
| Autistic Disorder | 3 | 2022 | 319 | 0.230 |
Why?
|
| Developmental Disabilities | 6 | 2016 | 674 | 0.230 |
Why?
|
| Anesthetics, Intravenous | 2 | 2001 | 73 | 0.220 |
Why?
|
| Clinical Competence | 1 | 2011 | 1270 | 0.220 |
Why?
|
| Hallucinations | 1 | 2003 | 35 | 0.220 |
Why?
|
| Epilepsy, Temporal Lobe | 2 | 2001 | 101 | 0.220 |
Why?
|
| Neurophysiology | 2 | 2013 | 20 | 0.220 |
Why?
|
| Emergency Service, Hospital | 3 | 2018 | 1148 | 0.220 |
Why?
|
| Phenobarbital | 3 | 2020 | 48 | 0.220 |
Why?
|
| Piracetam | 2 | 2013 | 11 | 0.210 |
Why?
|
| Temporal Lobe | 4 | 2004 | 192 | 0.210 |
Why?
|
| Psychosurgery | 1 | 2001 | 28 | 0.200 |
Why?
|
| Electrodes | 2 | 2020 | 116 | 0.200 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 1999 | 156 | 0.200 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2021 | 42 | 0.200 |
Why?
|
| Epilepsies, Myoclonic | 2 | 1998 | 28 | 0.190 |
Why?
|
| Language Development Disorders | 1 | 2022 | 167 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 1226 | 0.190 |
Why?
|
| Acidosis | 2 | 2002 | 116 | 0.190 |
Why?
|
| Hypothermia, Induced | 3 | 2001 | 170 | 0.190 |
Why?
|
| Epilepsy, Absence | 3 | 1998 | 35 | 0.190 |
Why?
|
| Electric Stimulation | 4 | 2011 | 426 | 0.190 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 624 | 0.180 |
Why?
|
| Drug Interactions | 2 | 2018 | 553 | 0.180 |
Why?
|
| Stroke | 3 | 2021 | 1144 | 0.180 |
Why?
|
| Photoperiod | 1 | 2019 | 31 | 0.180 |
Why?
|
| Hospitalization | 5 | 2022 | 2083 | 0.170 |
Why?
|
| Positron-Emission Tomography | 2 | 2008 | 2173 | 0.170 |
Why?
|
| Neocortex | 2 | 2004 | 98 | 0.160 |
Why?
|
| Brain Mapping | 4 | 2018 | 644 | 0.160 |
Why?
|
| Complementary Therapies | 1 | 1999 | 126 | 0.160 |
Why?
|
| Drug Evaluation | 1 | 2018 | 425 | 0.160 |
Why?
|
| Craniotomy | 1 | 2000 | 304 | 0.150 |
Why?
|
| Neurosurgical Procedures | 3 | 2011 | 609 | 0.150 |
Why?
|
| 4-Aminobutyrate Transaminase | 1 | 2017 | 8 | 0.150 |
Why?
|
| Carrier Proteins | 2 | 2018 | 2022 | 0.150 |
Why?
|
| Cyclosporine | 1 | 1998 | 278 | 0.150 |
Why?
|
| Infusions, Intravenous | 3 | 2018 | 1382 | 0.150 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2016 | 32 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2021 | 621 | 0.140 |
Why?
|
| Cerebral Infarction | 2 | 1995 | 59 | 0.140 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2017 | 105 | 0.140 |
Why?
|
| Neuromyelitis Optica | 1 | 1996 | 26 | 0.140 |
Why?
|
| Mydriasis | 1 | 1995 | 7 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2020 | 636 | 0.140 |
Why?
|
| Inpatients | 1 | 2021 | 678 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 1998 | 191 | 0.130 |
Why?
|
| Frontal Lobe | 3 | 2015 | 187 | 0.130 |
Why?
|
| Time Factors | 8 | 2021 | 12926 | 0.130 |
Why?
|
| Diagnosis, Differential | 11 | 2017 | 4744 | 0.130 |
Why?
|
| Life Support Care | 1 | 2015 | 50 | 0.130 |
Why?
|
| Amobarbital | 1 | 2015 | 6 | 0.130 |
Why?
|
| Muscle Hypotonia | 1 | 2016 | 180 | 0.130 |
Why?
|
| Age Factors | 8 | 2020 | 5377 | 0.130 |
Why?
|
| Recurrence | 2 | 2020 | 4758 | 0.130 |
Why?
|
| Gestational Age | 1 | 2018 | 1069 | 0.130 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 14889 | 0.120 |
Why?
|
| Prospective Studies | 10 | 2021 | 12873 | 0.120 |
Why?
|
| Port-Wine Stain | 1 | 2014 | 7 | 0.120 |
Why?
|
| Young Adult | 11 | 2023 | 21445 | 0.120 |
Why?
|
| Sturge-Weber Syndrome | 1 | 2014 | 10 | 0.120 |
Why?
|
| Intellectual Disability | 3 | 2016 | 1032 | 0.120 |
Why?
|
| Carbon Dioxide | 2 | 2001 | 313 | 0.120 |
Why?
|
| Brain Edema | 2 | 2010 | 86 | 0.120 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2018 | 413 | 0.120 |
Why?
|
| Epilepsy, Tonic-Clonic | 4 | 1999 | 16 | 0.120 |
Why?
|
| Cytokines | 1 | 2023 | 2809 | 0.120 |
Why?
|
| Lorazepam | 1 | 2013 | 40 | 0.110 |
Why?
|
| Cyclohexanecarboxylic Acids | 3 | 1998 | 42 | 0.110 |
Why?
|
| Drug Administration Schedule | 5 | 2018 | 3472 | 0.110 |
Why?
|
| Drug Therapy, Combination | 5 | 2001 | 2315 | 0.110 |
Why?
|
| Drug Resistance | 2 | 2005 | 587 | 0.110 |
Why?
|
| Hospital Mortality | 2 | 2021 | 1274 | 0.110 |
Why?
|
| Amines | 3 | 1998 | 85 | 0.110 |
Why?
|
| Delta Rhythm | 1 | 1992 | 3 | 0.110 |
Why?
|
| Leukomalacia, Periventricular | 1 | 2012 | 13 | 0.110 |
Why?
|
| Acetates | 3 | 1998 | 105 | 0.110 |
Why?
|
| Adult | 17 | 2023 | 77950 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1996 | 461 | 0.110 |
Why?
|
| Munc18 Proteins | 1 | 2012 | 39 | 0.110 |
Why?
|
| Hospitals, Pediatric | 3 | 2022 | 773 | 0.100 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2013 | 137 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2013 | 249 | 0.100 |
Why?
|
| Cerebrum | 1 | 2012 | 44 | 0.100 |
Why?
|
| Administration, Intravenous | 1 | 2013 | 249 | 0.100 |
Why?
|
| Laughter | 1 | 2011 | 12 | 0.100 |
Why?
|
| Mental Disorders | 1 | 1999 | 862 | 0.100 |
Why?
|
| Malformations of Cortical Development | 1 | 2012 | 57 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 481 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 6009 | 0.100 |
Why?
|
| Gain of Function Mutation | 2 | 2023 | 126 | 0.100 |
Why?
|
| Cerebrovascular Disorders | 1 | 1992 | 142 | 0.100 |
Why?
|
| Weights and Measures | 1 | 2010 | 7 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2012 | 290 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 1992 | 183 | 0.100 |
Why?
|
| Brain Stem | 2 | 1990 | 175 | 0.100 |
Why?
|
| Trisomy | 1 | 2012 | 231 | 0.100 |
Why?
|
| Evoked Potentials, Motor | 1 | 2011 | 58 | 0.100 |
Why?
|
| Molecular Chaperones | 1 | 2012 | 264 | 0.100 |
Why?
|
| Dexamethasone | 1 | 1996 | 1450 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 1491 | 0.100 |
Why?
|
| Plasmapheresis | 1 | 1990 | 61 | 0.100 |
Why?
|
| Autoantibodies | 2 | 2023 | 576 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1046 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2012 | 327 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2013 | 1648 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2013 | 414 | 0.090 |
Why?
|
| Hepatic Encephalopathy | 1 | 1990 | 66 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 544 | 0.090 |
Why?
|
| Spectrum Analysis | 1 | 2010 | 139 | 0.090 |
Why?
|
| Neuroimaging | 1 | 2013 | 403 | 0.090 |
Why?
|
| Critical Pathways | 1 | 2011 | 149 | 0.090 |
Why?
|
| Neurogenesis | 1 | 2012 | 238 | 0.090 |
Why?
|
| Leukoencephalopathies | 1 | 2010 | 63 | 0.090 |
Why?
|
| Meningeal Neoplasms | 1 | 2014 | 441 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2021 | 9244 | 0.090 |
Why?
|
| Monitoring, Intraoperative | 1 | 2011 | 264 | 0.090 |
Why?
|
| Algorithms | 2 | 2011 | 3890 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 383 | 0.090 |
Why?
|
| Hypothalamus | 1 | 2011 | 255 | 0.090 |
Why?
|
| Electrodes, Implanted | 4 | 2018 | 183 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 487 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 698 | 0.090 |
Why?
|
| Kainic Acid | 1 | 2008 | 32 | 0.080 |
Why?
|
| Consensus | 1 | 2013 | 978 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2010 | 2796 | 0.080 |
Why?
|
| Rats, Long-Evans | 1 | 2008 | 101 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 862 | 0.080 |
Why?
|
| Cerebral Aqueduct | 1 | 1988 | 8 | 0.080 |
Why?
|
| Occupations | 1 | 2008 | 50 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2008 | 305 | 0.080 |
Why?
|
| Brain Death | 1 | 1988 | 53 | 0.080 |
Why?
|
| Statistics, Nonparametric | 3 | 2018 | 980 | 0.080 |
Why?
|
| Phenotype | 4 | 2023 | 6295 | 0.080 |
Why?
|
| Infant, Premature | 1 | 1992 | 787 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2012 | 1385 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 726 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2012 | 1442 | 0.070 |
Why?
|
| Toxicology | 1 | 2006 | 14 | 0.070 |
Why?
|
| Brain Diseases, Metabolic, Inborn | 1 | 2006 | 23 | 0.070 |
Why?
|
| Spinal Cord Injuries | 1 | 1990 | 374 | 0.070 |
Why?
|
| Postoperative Complications | 5 | 1997 | 5542 | 0.070 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2010 | 362 | 0.070 |
Why?
|
| Spinal Puncture | 1 | 2006 | 63 | 0.070 |
Why?
|
| Neurofibromatosis 1 | 1 | 1988 | 144 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 118 | 0.070 |
Why?
|
| Career Choice | 1 | 2008 | 232 | 0.070 |
Why?
|
| Thiopental | 1 | 2005 | 7 | 0.070 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 998 | 0.070 |
Why?
|
| United States | 5 | 2018 | 15433 | 0.070 |
Why?
|
| Evoked Potentials | 3 | 1995 | 190 | 0.070 |
Why?
|
| Evoked Potentials, Somatosensory | 3 | 1996 | 60 | 0.070 |
Why?
|
| Hypoxia | 1 | 1988 | 443 | 0.070 |
Why?
|
| Prognosis | 6 | 2011 | 21713 | 0.070 |
Why?
|
| Cerebral Ventricles | 1 | 2005 | 98 | 0.070 |
Why?
|
| Choristoma | 1 | 2005 | 85 | 0.060 |
Why?
|
| Fentanyl | 2 | 2011 | 148 | 0.060 |
Why?
|
| Nervous System | 1 | 2005 | 165 | 0.060 |
Why?
|
| Motor Skills Disorders | 1 | 2004 | 20 | 0.060 |
Why?
|
| Bicarbonates | 2 | 2002 | 130 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2054 | 0.060 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2005 | 176 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 4849 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 276 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 2307 | 0.060 |
Why?
|
| Communicable Diseases | 1 | 2006 | 193 | 0.060 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 2 | 1996 | 31 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2003 | 7551 | 0.060 |
Why?
|
| Epilepsy, Complex Partial | 1 | 2003 | 18 | 0.060 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 38 | 0.060 |
Why?
|
| Paresthesia | 1 | 2003 | 33 | 0.060 |
Why?
|
| 4-Aminopyridine | 1 | 2023 | 41 | 0.060 |
Why?
|
| Huntington Disease | 1 | 2004 | 135 | 0.060 |
Why?
|
| Pharyngeal Diseases | 1 | 2003 | 53 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2018 | 1544 | 0.060 |
Why?
|
| Kv1.1 Potassium Channel | 1 | 2023 | 39 | 0.060 |
Why?
|
| Oligodendroglia | 1 | 2023 | 96 | 0.060 |
Why?
|
| Ketosis | 1 | 2002 | 16 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 1994 | 1697 | 0.050 |
Why?
|
| Pharynx | 1 | 2003 | 153 | 0.050 |
Why?
|
| Intraoperative Care | 2 | 2001 | 259 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2022 | 38 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 573 | 0.050 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2022 | 37 | 0.050 |
Why?
|
| Device Approval | 1 | 2001 | 21 | 0.050 |
Why?
|
| Neurologic Examination | 4 | 2001 | 245 | 0.050 |
Why?
|
| Craniocerebral Trauma | 1 | 2003 | 130 | 0.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 598 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2023 | 6100 | 0.050 |
Why?
|
| Infectious Encephalitis | 1 | 2020 | 5 | 0.050 |
Why?
|
| Long-Term Care | 1 | 2001 | 83 | 0.050 |
Why?
|
| Wakefulness | 2 | 2012 | 150 | 0.050 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2001 | 26 | 0.050 |
Why?
|
| Dominance, Cerebral | 3 | 1997 | 81 | 0.050 |
Why?
|
| Diet, Ketogenic | 1 | 2021 | 22 | 0.050 |
Why?
|
| Age of Onset | 2 | 2004 | 827 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 5687 | 0.050 |
Why?
|
| Incidence | 1 | 2011 | 5673 | 0.050 |
Why?
|
| Cannabidiol | 1 | 2021 | 42 | 0.050 |
Why?
|
| Immune System Diseases | 1 | 2021 | 65 | 0.050 |
Why?
|
| Atrophy | 1 | 2001 | 261 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 1351 | 0.050 |
Why?
|
| Rats | 1 | 2008 | 6086 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2000 | 246 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2001 | 295 | 0.040 |
Why?
|
| Organotechnetium Compounds | 2 | 1996 | 44 | 0.040 |
Why?
|
| Telemetry | 2 | 1997 | 39 | 0.040 |
Why?
|
| Child Development | 1 | 2001 | 255 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2006 | 1162 | 0.040 |
Why?
|
| Reticular Formation | 1 | 1998 | 4 | 0.040 |
Why?
|
| Excitatory Amino Acids | 1 | 1998 | 8 | 0.040 |
Why?
|
| Psychotropic Drugs | 1 | 1999 | 133 | 0.040 |
Why?
|
| Hemiplegia | 2 | 1995 | 47 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2006 | 1589 | 0.040 |
Why?
|
| Fever | 1 | 2021 | 497 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2018 | 231 | 0.040 |
Why?
|
| Receptors, GABA-B | 1 | 1998 | 33 | 0.040 |
Why?
|
| Receptors, GABA-A | 1 | 1998 | 79 | 0.040 |
Why?
|
| Triazines | 1 | 1998 | 117 | 0.040 |
Why?
|
| Acid-Base Equilibrium | 1 | 1997 | 78 | 0.040 |
Why?
|
| Flumazenil | 1 | 2017 | 8 | 0.040 |
Why?
|
| GABA Modulators | 1 | 2017 | 15 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 330 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2007 | 6869 | 0.040 |
Why?
|
| Pyramidal Cells | 1 | 1998 | 168 | 0.040 |
Why?
|
| Models, Neurological | 1 | 1998 | 225 | 0.040 |
Why?
|
| Fixation, Ocular | 1 | 1996 | 58 | 0.040 |
Why?
|
| Memory | 1 | 2000 | 429 | 0.030 |
Why?
|
| Motor Activity | 1 | 2000 | 693 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 1997 | 297 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 7222 | 0.030 |
Why?
|
| Biopsy | 1 | 2003 | 3443 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 1995 | 141 | 0.030 |
Why?
|
| Child Behavior Disorders | 1 | 1996 | 68 | 0.030 |
Why?
|
| Cysteine | 1 | 1996 | 214 | 0.030 |
Why?
|
| Cerebral Decortication | 1 | 1994 | 1 | 0.030 |
Why?
|
| Polysomnography | 2 | 2012 | 155 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 2139 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 3719 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2001 | 1529 | 0.030 |
Why?
|
| Somatoform Disorders | 1 | 1995 | 61 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1997 | 422 | 0.030 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2015 | 171 | 0.030 |
Why?
|
| Animals | 3 | 2008 | 59536 | 0.030 |
Why?
|
| Psychophysiologic Disorders | 1 | 1995 | 29 | 0.030 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1995 | 84 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 2218 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2001 | 4320 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2015 | 240 | 0.030 |
Why?
|
| Cognition | 1 | 2000 | 968 | 0.030 |
Why?
|
| Video Recording | 1 | 1995 | 267 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 4298 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2016 | 1258 | 0.030 |
Why?
|
| Endoglin | 1 | 2012 | 43 | 0.030 |
Why?
|
| Language | 1 | 2015 | 309 | 0.030 |
Why?
|
| Mammillary Bodies | 1 | 2011 | 3 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 543 | 0.030 |
Why?
|
| Canada | 1 | 2013 | 429 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 4988 | 0.030 |
Why?
|
| Child Behavior | 3 | 2001 | 243 | 0.030 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2011 | 8 | 0.030 |
Why?
|
| Intelligence | 1 | 2012 | 126 | 0.030 |
Why?
|
| Cerebral Palsy | 1 | 1992 | 63 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 6682 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2012 | 173 | 0.030 |
Why?
|
| Dehydration | 1 | 1991 | 87 | 0.020 |
Why?
|
| Pyramidal Tracts | 1 | 2011 | 57 | 0.020 |
Why?
|
| Mutation | 2 | 2023 | 15179 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 1995 | 1178 | 0.020 |
Why?
|
| Haploinsufficiency | 1 | 2012 | 294 | 0.020 |
Why?
|
| Exome | 1 | 2016 | 1239 | 0.020 |
Why?
|
| Quadriplegia | 1 | 1990 | 43 | 0.020 |
Why?
|
| Genotype | 1 | 2018 | 4109 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2011 | 204 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1995 | 1581 | 0.020 |
Why?
|
| Quality of Life | 2 | 2021 | 4532 | 0.020 |
Why?
|
| Arnold-Chiari Malformation | 1 | 1990 | 43 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 691 | 0.020 |
Why?
|
| Leigh Disease | 1 | 1990 | 39 | 0.020 |
Why?
|
| Spine | 1 | 2011 | 293 | 0.020 |
Why?
|
| Asparaginase | 1 | 2010 | 184 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2011 | 239 | 0.020 |
Why?
|
| Safety | 1 | 2011 | 465 | 0.020 |
Why?
|
| Primidone | 1 | 1988 | 8 | 0.020 |
Why?
|
| Risk Factors | 2 | 2004 | 17523 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2001 | 585 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1997 | 1237 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1945 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 15862 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 829 | 0.020 |
Why?
|
| Premature Birth | 1 | 2012 | 407 | 0.020 |
Why?
|
| Neurons | 1 | 1998 | 2287 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 2232 | 0.020 |
Why?
|
| Methotrexate | 1 | 2010 | 999 | 0.020 |
Why?
|
| Spinal Cord | 1 | 1990 | 690 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 615 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 1544 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 3203 | 0.020 |
Why?
|
| Vincristine | 1 | 2010 | 1511 | 0.020 |
Why?
|
| Myelin Basic Protein | 1 | 2005 | 85 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2005 | 46 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2005 | 115 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2011 | 674 | 0.020 |
Why?
|
| Survival Rate | 1 | 1999 | 12221 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2011 | 899 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2011 | 786 | 0.020 |
Why?
|
| Occipital Lobe | 1 | 2004 | 48 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2005 | 347 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 4892 | 0.020 |
Why?
|
| Auditory Cortex | 1 | 2004 | 38 | 0.020 |
Why?
|
| Cytarabine | 1 | 2010 | 1973 | 0.010 |
Why?
|
| Videotape Recording | 1 | 2003 | 74 | 0.010 |
Why?
|
| Comorbidity | 2 | 2003 | 2352 | 0.010 |
Why?
|
| Organ Size | 1 | 2004 | 690 | 0.010 |
Why?
|
| Urinary Calculi | 1 | 2002 | 25 | 0.010 |
Why?
|
| Middle Aged | 1 | 2009 | 86204 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 1489 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 1021 | 0.010 |
Why?
|
| Body Temperature | 1 | 2001 | 158 | 0.010 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2001 | 133 | 0.010 |
Why?
|
| Transposition of Great Vessels | 1 | 2001 | 124 | 0.010 |
Why?
|
| Tetralogy of Fallot | 1 | 2001 | 149 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2005 | 1048 | 0.010 |
Why?
|
| Histones | 1 | 2005 | 1466 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 11965 | 0.010 |
Why?
|
| Computer Systems | 1 | 1997 | 106 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 5637 | 0.010 |
Why?
|
| Akathisia, Drug-Induced | 1 | 1996 | 14 | 0.010 |
Why?
|
| Suggestion | 1 | 1995 | 4 | 0.010 |
Why?
|
| Television | 1 | 1996 | 74 | 0.010 |
Why?
|
| Brain Damage, Chronic | 1 | 1995 | 37 | 0.010 |
Why?
|
| Subdural Space | 1 | 1995 | 7 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1994 | 10 | 0.010 |
Why?
|
| Migraine Disorders | 1 | 1996 | 79 | 0.010 |
Why?
|
| Electric Countershock | 1 | 1995 | 71 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 7548 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 276 | 0.010 |
Why?
|
| Aggression | 1 | 1996 | 252 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1997 | 935 | 0.010 |
Why?
|
| Oximes | 1 | 1994 | 175 | 0.010 |
Why?
|
| Speech | 1 | 1995 | 133 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1999 | 2588 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1996 | 471 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 1996 | 274 | 0.010 |
Why?
|
| Heart Rate | 1 | 1995 | 737 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 8865 | 0.010 |
Why?
|
| Tectum Mesencephali | 1 | 1990 | 2 | 0.010 |
Why?
|
| Putamen | 1 | 1990 | 26 | 0.010 |
Why?
|
| Caudate Nucleus | 1 | 1990 | 43 | 0.010 |
Why?
|
| Globus Pallidus | 1 | 1990 | 71 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1995 | 1145 | 0.010 |
Why?
|
| Contrast Media | 1 | 1990 | 1472 | 0.000 |
Why?
|